ACTRN12617000456358
Completed
Phase 4
Efficacy and safety of the medications of first line treatment (artesunate+amodiaquine) and second line treatment (artemether+lumefantrine) for the treatment of uncomplicated Plasmodium falciparum in Malabo, Bata and Ebibey, Equatorial Guinee
Ministry of Public Health of Equatorial Guinea0 sites528 target enrollmentMarch 28, 2017
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ministry of Public Health of Equatorial Guinea
- Enrollment
- 528
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. age from 6 to 59 months;
- •2\. mono\-infection with P. falciparum detected by microscopy;
- •3\. parasitaemia of 1000–200,000/microliter asexual forms;
- •4\. presence of axillary temperature greater or equal to 37\.5 degrees C or history of fever during the past 24 h
- •5\. ability to swallow oral medication;
- •6\. ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule;
- •7\. informed consent from the patient or parent/ guardian of children.
Exclusion Criteria
- •1\. presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of WHO;
- •2\. weight under 5 kg;
- •4\. mixed or mono\-infection with another Plasmodium species detected by microscopy;
- •5\. presence of severe malnutrition defined as a child aged 6\-60 months has a mid\-upper arm circumference below 115 mm)
- •6\. presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, HIV/AIDS);
- •7\. regular medication, which may interfere with antimalarial pharmacokinetics;
- •8\. history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s).
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Efficacy and safety of initial treatment (combination immunotherapy or chemotherapy + ICI) in advanced non-small cell lung cancer patients (TPS 1-49%): A multicenter retrospective observational study (TOPGAN2023-01)non small cell carcinomaJPRN-UMIN000052228department of respiratory medicine hirosaki university graduate school of medicine300
Active, not recruiting
Phase 1
A Phase I/II Safety, Pharmacodynamic, and Pharmacokinetic Study of Intravenously Administered PXD101 Plus Carboplatin or Paclitaxel or Both in Patients with Advanced Solid Tumours - PXD101-040-EU Global V4In the MTD expansion arm only women with a history of epithelial ovarian, primary peritoneal, fallopian tube or mixed mullerian tumours of ovarian origin participate to confirm the safety and to examine efficacy in this specific patient population.MedDRA version: 8.1 Level: LLT Classification code 10033128 Term: Ovarian cancerEUCTR2005-002338-36-GBTopoTarget A/S65
Completed
Phase 1
Safety, efficacy and pharmacokinetic study of paclitaxel injection concentrate for nano-dispersion in subjects with metastatic breast cancer.CTRI/2009/091/000262Sun Pharma Advanced Research Company Ltd36
Recruiting
Phase 4
Clinical trial to compare the effectiveness of migraine’s preventive treatments in primary care2024-513597-22-00Institut Universitari D Investigacio En Atencion Primaria Jordi Gol460
Not yet recruiting
Not Applicable
Safety and efficacy on glaucoma treatment with 3 topical medicationsin one bottle x medications in separated bottlesopen angle glaucomaRBR-6kkmskkcentro oftalmologico de minas gerais